MASSY, FRANCE--(Marketwire - January 05, 2012) -
First clinical trial in Human is expected beginning 2012.
Quantum Genomics (NYSE Euronext Paris ticker MLQGC) announced today the
from the "Comité de Protection des Personnes (Ile de France VIII)" for
clinical trial in human of its leading compound QGC001.
QGC001 is the first of a new class of drugs that aim to treat high blood
pressure (HBP) - also called hypertension.
The application of this First-in-Human clinical trial has been submitted to
French Agency for Safety of Health Products (AFSSAPS).
This clinical trial will be a single ascending oral dose, double-blind and
placebo-controlled Phase I study. It will aim at assessing the overall
tolerability and pharmacokinetics of QGC001 in healthy volunteers.
An exploratory study conducted in parallel, in partnership with the «
d'Investigations Cliniques 9201/APHP-INSERM of the Hôpital
Pompidou (Paris, France) and thanks to the financial support from the
National Agency for Research (ANR), will aim at identifying relevant
to support the next coming phases of the clinical development.
"This approval from the "Comité de Protection des Personnes" is a
major step in
the development of QGC001 which reinforces the very good preclinical
says Lionel Segard, President and CEO of Quantum Genomics. QGC001 is a
breakthrough innovation that will bring hope to patients with a specific
profile, especially those who are usually not properly treated for their
hypertension despite several drugs and/or suffer from important side
Quantum Genomics is looking forward to starting the clinical trials in the
half of 2012, as soon as we get the approval from AFSSAPS."
About the "Comité de Protection des Personnes"
The approval from the "Comité de Protection des Personnes" relates to
ethical aspects of the study protocol and the documents proposed to get
volunteers' agreement. This is one of the two authorisations that are
to allow the company to start a clinical trial; the second one comes from
The objective of QGC001 is to offer a therapeutic alternative for the
of High Blood Pressure. The unique mechanism of action of QGC001 (selective
inhibition of brain aminopeptidase A) makes it a promising drug for the
treatment of hypertensive patients with Low Renin High Vasopressin profile
(LRHV), whose blood pressure is usually poorly controlled.
Hypertension (high blood pressure) affects an estimated 1 billion people
Despite several effective proven treatments, high blood pressure has proven
difficult to control in 30 to 60% of hypertensive patients (49% in France,
Girerd et al. 2008).
In addition, overall incidence of resistant hypertension to at least three
antihypertensive drugs (including a diuretic) is estimated( )to be 15% of
Low Renin and High Vasopressin profile (LRHV) is a common condition that
characterizes nearly 30% of all hypertensive patients that have reduced
to ACE inhibitors, angiotensin receptor blockers (ARBs), renin inhibitors
About Quantum Genomics.
QGC is a biotechnology company seeking to develop new therapies in areas
an unmet medical need exists. QGC is presently focused on the treatment of
It will co-develop those products with academic teams and will set up
alliances and commercial partnerships with larger company in order to make
The company is headquartered in Massy France under the leadership of Lionel
Ségard, supported by a management team of experienced people,
Balavoine (VP Research & Development) and Michel Lepers (VP Business
For more information go to www.quantum-genomics.com
Press release January 5 2012:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Quantum Genomics via Thomson Reuters ONE